Bimatoprost, a widely used medication for treating glaucoma and ocular hypertension, relies on intricate synthetic pathways. At the heart of many efficient synthesis routes for Bimatoprost lies a crucial intermediate: 1-Bromo-4-phenyl-2-butanone (CAS 31984-10-8). Understanding the properties and supply chain of this compound is essential for any pharmaceutical company involved in its production.

1-Bromo-4-phenyl-2-butanone is characterized by its chemical structure, which includes a phenyl group, a ketone functionality, and a reactive bromine atom. This reactive bromine atom is key, enabling nucleophilic substitution reactions that are fundamental in constructing the complex molecular architecture of Bimatoprost. The compound typically presents as a white crystalline powder, with a high assay of ≥98.0%, ensuring that the subsequent synthetic steps proceed with high fidelity and minimal unwanted byproducts.

For pharmaceutical manufacturers, ensuring a consistent and high-quality supply of 1-Bromo-4-phenyl-2-butanone is non-negotiable. Sourcing from a reputable manufacturer in China, a global hub for fine chemical production, offers significant advantages. These include access to advanced synthesis capabilities, competitive pricing, and a stable supply chain that can support both research and large-scale manufacturing requirements. When evaluating potential suppliers, look for those with rigorous quality control processes and a proven history in producing pharmaceutical intermediates.

The efficiency of the Bimatoprost synthesis is directly linked to the quality of its precursors. A pure intermediate like 1-Bromo-4-phenyl-2-butanone minimizes side reactions and simplifies downstream purification, ultimately reducing manufacturing costs and lead times. For procurement professionals and formulation scientists, identifying a dependable manufacturer who can provide technical support and reliable delivery is paramount. This ensures that production schedules are met and that the final API meets all regulatory and quality standards.

In essence, the successful synthesis of Bimatoprost is a testament to the strategic importance of intermediates like 1-Bromo-4-phenyl-2-butanone. By partnering with experienced chemical suppliers, pharmaceutical companies can optimize their production processes and contribute to the availability of vital treatments for eye conditions worldwide.